KAPA
KAPA
AMEX · Biotechnology

Kairos Pharma Ltd

$0.57
+0.01 (+2.16%)
Financial Highlights (FY 2025)
Revenue
5.65M
Net Income
307.3K
Gross Margin
65.2%
Profit Margin
5.4%
Rev Growth
+24.0%
D/E Ratio
0.71
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 65.2% 65.2% 65.2%
Operating Margin 6.0% 7.0% 6.4%
Profit Margin 5.4% 5.0% 6.6%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 5.65M 5.72M 5.36M
Gross Profit 3.68M 3.73M 3.50M
Operating Income 341.3K 402.5K 345.7K
Net Income 307.3K 283.7K 353.7K
Gross Margin 65.2% 65.2% 65.2%
Operating Margin 6.0% 7.0% 6.4%
Profit Margin 5.4% 5.0% 6.6%
Rev Growth +24.0% +14.6% +14.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 3.26M 3.51M 3.59M
Total Equity 4.61M 3.84M 3.90M
D/E Ratio 0.71 0.92 0.92
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 445.8K 473.3K 433.9K
Free Cash Flow 346.8K 407.6K 312.1K